Oric Pharmaceuticals

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced clearance of its Clinical Trial Application (CTA) by the regulatory authorities of the Republic of Korea for ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations.

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m. ET.

ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

CD73 inhibition overcomes immunosuppression and demonstrates activity in assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc.

ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide and preclinical data on ORIC-114 presented at AACR-NCI-EORTC

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

CD73 inhibition overcomes immune suppression and demonstrates activity in autologous ex vivo cell assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic

ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals Inc (NASDAQ: ORIC) announced initial data from Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. Data were presented at AACR-NCI-EORTC.

ORIC Pharma's Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress Investors

ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

Company to host conference call and webcast Thursday, October 7, 2021, at 9:00 a.m. ET Company to host conference call and webcast Thursday, October 7, 2021, at 9:00 a.m. ET

ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced an update on its CD73 inhibitor program. ORIC recently announced the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug Application (IND) for ORIC-533 to proceed into a first-in-human clinical trial in which ORIC-533 will be tested as a single agent in an undisclosed tumor type not currently known to be under clinical evaluation with any other CD73 inhibitor. ORIC-533 was discovered internally at ORIC, is wholly owned, and is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.

ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry veteran Steven L. Hoerter to its Board of Directors.

ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors

ORIC-101 on track for initial Phase 1b data readout in prostate cancer in 2H21

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

Oric Pharmaceuticals Inc (NASDAQ: ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in advanced solid tumors. Data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors

Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 p.m. ET.

ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that two abstracts highlighting preliminary results from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel have been accepted for poster presentations during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4 - 8, 2021.

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting.

ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Lead program ORIC-101 on track for two initial data readouts in 2021

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting on April 10-15, 2021.

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 12:40 p.m. PT.

ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

News for Oric Pharmaceuticals Stock (ORIC)